+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A pharmacokinetic and pharmacodynamic drug interaction between rosuvastatin and valsartan in healthy subjects



A pharmacokinetic and pharmacodynamic drug interaction between rosuvastatin and valsartan in healthy subjects



Drug Design Development and Therapy 9: 745-752



Valsartan, an angiotensin-receptor blocker, and rosuvastatin, a competitive inhibitor of the 3-hydroxy-3-methylglutaryl coenzyme A reductase, are frequently coadministered to treat patients with hypertension and dyslipidemia. The study reported here sought to evaluate the pharmacokinetic and pharmacodynamic interactions between rosuvastatin and valsartan in healthy Korean subjects. Thirty healthy male Korean subjects were administered with rosuvastatin (20 mg/day), valsartan (160 mg/day), and both drugs concomitantly for 4 days in a randomized, open-label, multiple-dose, three-treatment, three-period crossover study. Plasma concentrations of rosuvastatin, N-desmethyl rosuvastatin, and valsartan were determined using validated high-performance liquid chromatography with tandem mass spectrometry. Lipid profiles and vital signs (systolic and diastolic blood pressure and pulse rate) were measured for the pharmacodynamic assessment. For rosuvastatin, the geometric mean ratios (90% confidence intervals [CIs]) of coadministration to mono-administration were 0.8809 (0.7873-0.9857) for maximum plasma concentration at steady state and 0.9151 (0.8632-0.9701) for area under the concentration-time curve (AUC) over a dosing interval at steady state. For valsartan, the geometric mean ratios (90% CIs) of those were 0.9300 (0.7946-1.0884) and 1.0072 (0.8893-1.1406), respectively. There were no significant differences in the metabolic ratio of N-desmethyl rosuvastatin AUC to rosuvastatin AUC between coadministration and rosuvastatin alone. No interaction was found in terms of systolic or diastolic blood pressure or lipid profiles. Combined treatment with valsartan and rosuvastatin was generally well tolerated without serious adverse events. The pharmacokinetic profiles of rosuvastatin and valsartan in combination were comparable with those of rosuvastatin and valsartan administered individually, suggesting that their individual pharmacokinetics were not affected by their coadministration. No dose adjustment was required and the results are supportive of a study in a larger patient population.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 057084001

Download citation: RISBibTeXText

PMID: 25767372

DOI: 10.2147/dddt.s76942


Related references

Pharmacokinetic and pharmacodynamic interaction between ezetimibe and rosuvastatin in healthy male subjects. Drug Design Development and Therapy 11: 3461-3469, 2017

Pharmacokinetic Drug Interactions Between Amlodipine, Valsartan, and Rosuvastatin in Healthy Volunteers. Advances in Therapy 36(7): 1642-1656, 2019

Pharmacokinetic and Pharmacodynamic Evaluation of the Drug-Drug Interaction Between Isavuconazole and Warfarin in Healthy Subjects. Clinical Pharmacology in Drug Development 6(1): 86-92, 2017

Evaluation of the pharmacokinetic and pharmacodynamic drug interactions between cilnidipine and valsartan, in healthy volunteers. Drug Design Development and Therapy 8: 1781-1788, 2014

A validated Rp-Hplc method for the determination of rosuvastatin in presence of sacubitril/valsartan in rat plasma: Application to in vivo evaluation of Oatp-mediated drug interaction potential between rosuvastatin and sacubitril/valsartan. Microchemical Journal 143: 31-38, 2018

Evaluation of Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Sacubitril/Valsartan (LCZ696) and Sildenafil in Patients With Mild-to-Moderate Hypertension. Clinical Pharmacology and Therapeutics 103(3): 468-476, 2018

Evaluation of a pharmacokinetic interaction between valsartan and simvastatin in healthy subjects. Current Medical Research and Opinion 23(3): 631-640, 2007

Pharmacodynamic interaction between intravenous nitroglycerin and oral sacubitril/valsartan (LCZ696) in healthy subjects. European Journal of Clinical Pharmacology 74(9): 1121-1130, 2018

A Single-Center, Open-Label, 3-Way Crossover Trial to Determine the Pharmacokinetic and Pharmacodynamic Interaction Between Nebivolol and Valsartan in Healthy Volunteers at Steady State. American Journal of Therapeutics 22(5): E130-E140, 2016

Pharmacokinetic drug interaction study using fimasartan and rosuvastatin in healthy volunteers. International Journal of Clinical Pharmacology and Therapeutics 54(12): 992, 2016

Pharmacokinetic Drug Interaction Between Rosuvastatin and Tanjin in Healthy Volunteers and Rats. Yonago Acta Medica 62(1): 77-84, 2019

Pharmacokinetic and pharmacodynamic interaction between gemigliptin and metformin in healthy subjects. Clinical Drug Investigation 34(6): 383-393, 2014

Pharmacokinetic and Pharmacodynamic Interaction Between Tolvaptan and Warfarin in Healthy Subjects. Clinical Pharmacology in Drug Development 1(2): 67-75, 2012

Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects. Clinical Pharmacokinetics 47(2): 111-118, 2008

Pharmacokinetic and pharmacodynamic interaction of siponimod (BAF312) and propranolol in healthy subjects. International Journal of Clinical Pharmacology and Therapeutics 53(10): 855-865, 2015